相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis
J. Doms et al.
ANNALS OF ONCOLOGY (2020)
Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation
Thoetchai (Bee) Peeraphatdit et al.
HEPATOLOGY (2020)
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Filipe Martins et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Fulminant hepatitis as an immune-related adverse event after nivolumab treatment
Osamu Inamori et al.
PATHOLOGY INTERNATIONAL (2019)
Checkpoint inhibitor-induced liver injury: A novel form of liver disease emerging in the era of cancer immunotherapy
Yoh Zen et al.
SEMINARS IN DIAGNOSTIC PATHOLOGY (2019)
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities
Filipe Martins et al.
LANCET ONCOLOGY (2019)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (vol 28, pg 119, 2017)
J. B. A. G. Haanen et al.
ANNALS OF ONCOLOGY (2018)
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
Eleonora De Martin et al.
JOURNAL OF HEPATOLOGY (2018)
Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury
Yoh Zen et al.
MODERN PATHOLOGY (2018)
Mortality due to immunotherapy related hepatitis
Prachi Bhave et al.
JOURNAL OF HEPATOLOGY (2018)
IL-6 Promotes T Cell Proliferation and Expansion under Inflammatory Conditions in Association with Low-Level RORγt Expression
Bofeng Li et al.
JOURNAL OF IMMUNOLOGY (2018)
A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy
Alice Horisberger et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Immune-suppressive effects of interleukin-6 on T-cell-mediated anti-tumor immunity
Hirotake Tsukamoto et al.
CANCER SCIENCE (2018)
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
I. Puzanov et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
Lars Hofmann et al.
EUROPEAN JOURNAL OF CANCER (2016)
CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt
Marie-Luise Berres et al.
JOURNAL OF HEPATOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
CXCL10 plays a key role as an inflammatory mediator and a non-invasive biomarker of non-alcoholic steatohepatitis
Xiang Zhang et al.
JOURNAL OF HEPATOLOGY (2014)
Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy
Katarzyna D. Chmiel et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
IL-6: Regulator of Treg/Th17 balance
Akihiro Kimura et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Hepatic Expression Patterns of Inflammatory and Immune Response Genes Associated with Obesity and NASH in Morbidly Obese Patients
Adeline Bertola et al.
PLOS ONE (2010)
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Loise M. Francisco et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
分享论文
